Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

433
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
433
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

492
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
492
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

488
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
488
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

521
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
521
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

321
Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
321
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

361
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
361

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exercise Performance With Aficamten vs Metoprolol in Obstructive Hypertrophic Cardiomyopathy: The MAPLE-HCM Randomized Clinical Trial.

JAMA cardiology·2026
Same author

Use of the IlluminOss Photodynamic Bone Stabilisation System Following Stereotactic Body Radiation Therapy for Limb-Sparing in Six Dogs With Presumptive Appendicular Osteosarcoma.

Veterinary and comparative oncology·2026
Same author

Cryptic splicing in synaptic and membrane excitability genes links TDP-43 loss to neuronal dysfunction.

Science translational medicine·2026
Same author

Median Survival Among Patients Hospitalized for Heart Failure with Reduced Ejection Fraction Prescribed Quadruple Medical Therapy.

European journal of heart failure·2026
Same author

Towards a Quantitative Understanding of Aficamten Clinical Pharmacology: Pharmacokinetic-Cardiodynamic Modeling to Support Safety and Efficacy.

CPT: pharmacometrics & systems pharmacology·2026
Same author

Efficacy of Aficamten in Hypertrophic Cardiomyopathy Patients With Very-High Left Ventricular Outflow Tract Gradients.

The American journal of cardiology·2026

Related Experiment Video

Updated: Jan 22, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.2K

Machine learning detection of obstructive hypertrophic cardiomyopathy using a wearable biosensor.

Eric M Green1, Reinier van Mourik2, Charles Wolfus1

  • 1MyoKardia, Inc., South San Francisco, CA USA.

NPJ Digital Medicine
|July 16, 2019
PubMed
Summary

Smartwatches may soon screen for hypertrophic cardiomyopathy (HCM), a serious heart condition. Photoplethysmography analysis from watches identified obstructive HCM with high accuracy, aiding early diagnosis.

Keywords:
Diagnostic markersTranslational research

More Related Videos

Asthma Detection Research Based on Voice Signal Processing and Machine Learning
04:04

Asthma Detection Research Based on Voice Signal Processing and Machine Learning

Published on: July 22, 2025

943
Machine Learning Algorithms for Early Detection of Bone Metastases in an Experimental Rat Model
07:15

Machine Learning Algorithms for Early Detection of Bone Metastases in an Experimental Rat Model

Published on: August 16, 2020

7.4K

Related Experiment Videos

Last Updated: Jan 22, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.2K
Asthma Detection Research Based on Voice Signal Processing and Machine Learning
04:04

Asthma Detection Research Based on Voice Signal Processing and Machine Learning

Published on: July 22, 2025

943
Machine Learning Algorithms for Early Detection of Bone Metastases in an Experimental Rat Model
07:15

Machine Learning Algorithms for Early Detection of Bone Metastases in an Experimental Rat Model

Published on: August 16, 2020

7.4K

Area of Science:

  • Cardiology
  • Biomedical Engineering
  • Medical Diagnostics

Background:

  • Hypertrophic cardiomyopathy (HCM) is a genetic heart muscle disease with significant risks, including heart failure and sudden death.
  • Current diagnosis rates are low (10-20%), highlighting the need for accessible, non-clinical screening methods.
  • Photoplethysmography (PPG) is a noninvasive optical technique measuring blood volume changes, commonly available in smartwatches.

Purpose of the Study:

  • To evaluate the efficacy of PPG-based analysis for detecting obstructive HCM (oHCM).
  • To develop and validate a machine learning classifier for oHCM screening using PPG data.

Main Methods:

  • Collected PPG recordings and echocardiograms from 19 oHCM patients and 64 healthy controls.
  • Utilized automated analysis to compare 42 morphometric pulse wave features between groups.
  • Developed a machine learning classifier to distinguish oHCM from controls.

Main Results:

  • Significant differences (38/42 features) were observed in pulse wave morphology between oHCM patients and controls.
  • The machine learning classifier achieved a high C-statistic of 0.99 for oHCM detection.
  • Key differentiating features included systolic ejection time, rate of rise, and respiratory variation.

Conclusions:

  • PPG analysis combined with machine learning shows promise as a noninvasive screening tool for oHCM.
  • This technology could significantly improve early detection rates for hypertrophic cardiomyopathy.
  • Further development may lead to a widely accessible screening method for obstructive HCM via smartwatches.